ACC 2023 – Merck’s oral cholesterol lowerer shows mid-stage promise
The oral PCSK9 project MK-0616 meets its targets in phase 2, which could be bad news for Novartis.
ACC 2023 – Esperion’s outcomes win looks lacklustre
A 13% reduction in the risk of cardiovascular events is statistically significant but not spectacular.
US deal watchdog's bark could be worse than its bite
Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?
